Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

151.56 +0.16 (+0.10%)
Streaming Delayed Price Updated: 9:52 AM EST, Feb 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Gilead Sciences

< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
51 52 Next >
News headline image
3 Top Pharma Stocks to Buy Now: February 2024 ↗
Discover why these three pharma stocks should be on your buy list in February 2024 - they could be your ticket to explosive portfolio growth. 
Via InvestorPlace
News headline image
A New COVID-19 Variant Is Rapidly Spreading Around The Globe, Other Pandemic Threats Exist – What Are The Choices For Treatment? ↗
Colds, flu and RSV aren't the only viral illnesses people have to worry about this winter. A new variant of COVID-19 is rapidly spreading, reminding the world of just how dangerous this virus is. 
Via Benzinga
News headline image
Pharma Giant Gilead Raises Stake In Cancer-Focused Arcus Biosciences, Stock Soars ↗
Arcus Biosciences sees a 17.1% surge as Gilead Sciences amends collaboration, investing $320M at $21.00/share. Accelerate joint programs in cancer therapy. 
Via Benzinga
News headline image
Roche Walks Away From HOOKIPA Pharma-Partnered KRAS-Focused Cancer Deal ↗
HOOKIPA Pharma's strategic focus on HB-200 program for HPV16+ HNSCC, infectious disease cure collaboration with Gilead, and recent developments. 
Via Benzinga
News headline image
Behind the Scenes of Gilead Sciences's Latest Options Trends ↗
 
Via Benzinga
News headline image
If You Invested $100 In This Stock 20 Years Ago, You Would Have $1,000 Today ↗
 
Via Benzinga
News headline image
$1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
NASDAQ:GILD is probably undervalued for the fundamentals it is displaying. ↗
GILEAD SCIENCES INC (NASDAQ:GILD) is an undervalued gem with solid fundamentals. 
Via Chartmill
News headline image
Despite its impressive fundamentals, NASDAQ:GILD remains undervalued. ↗
When you look at GILEAD SCIENCES INC (NASDAQ:GILD), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. 
Via Chartmill
News headline image
Gilead's Tecartus Dropped From FDA List Of CAR-T Therapy With Updated Label Warning Of "Risks Of Secondary Cancer' ↗
FDA issues classwide black box warning for CAR-T therapies due to T-cell cancer risk. Drops Gilead's cell therapy from the list. 
Via Benzinga
News headline image
Focus On Bristol Myers, Gilead Sciences, Johnson & Johnson, Novartis: FDA To Issue Classwide Black Box Warning on CAR-T Therapies For Blood Cancer Treatment ↗
In a significant development, the FDA is set to impose a classwide black box warning following its investigation into secondary T-cell cancers arising from the use of existing CAR-T therapies.  
Via Benzinga
News headline image
7 Speculative Stocks to Double Your Money THIS Year ↗
Although terribly risky, these stocks to double your money could be enticing if you have some pocket change lying around. 
Via InvestorPlace
News headline image
Momentum Shifts Back To Tech Stocks As Healthcare Lags In 2024 ↗
Small Cap traders are taking a break in 2024 as XBI is down 2.51% YTD. 
Via Talk Markets
News headline image
Why Gilead Sciences Stock Got Mashed on Monday ↗
A late-stage trial of an otherwise successful cancer drug failed to produce the desired results. 
Via The Motley Fool
News headline image
S&P 500, Dow Extend All-Time Highs: 'It's A Lot Of Fun For Stock Investors While It Lasts,' Wall Street Veteran Says ↗
Stock market continues upward trend, with all major indexes reaching record highs. Wall Street veteran Ed Yardeni outlines three possible scenarios. 
Via Benzinga
Topics Stocks
News headline image
Dow Gains Over 100 Points; Archer-Daniels-Midland Shares Plunge ↗
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 100 points on Monday. The Dow traded up 0.27% to 37,967.81 while the NASDAQ rose 0.31% to 15,358.70. The... 
Via Benzinga
Topics Stocks
News headline image
S&P 500, Nasdaq, Dow Jones Strike All-Time Highs Ahead Of Key Earnings This Week: What's Driving Markets Monday? ↗
US stocks rise to record highs on strong earnings reports, with small caps outperforming. Dollar steady, gold down, oil up. Bitcoin tumbles. AMD, TSLA, ADM, GILD, WDC top movers. GE, AAPL, FB, AMZN,... 
Via Benzinga
Topics Stocks
News headline image
Why CommScope Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Shares of CommScope Holding Company, Inc. (NASDAQ: COMM) fell sharply during Monday’s session. B of A Securities analyst Tal Liani downgraded CommScope from Neutral to Underperform and lowered the... 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Crude Oil Surges Over 2%; US Leading Economic Index Falls In December ↗
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining around 150 points on Monday. The Dow traded up 0.41% to 38,018.23 while the NASDAQ rose 0.30% to 15,356.67. The S&P... 
Via Benzinga
Topics Stocks
News headline image
Why Is HIV Drug Giant Gilead Stock Falling Monday? ↗
Gilead's Phase 3 EVOKE-01 study on Trodelvy in metastatic non-small cell lung cancer didn't meet overall survival endpoint. Despite numerical OS improvement, further exploration is planned. 
Via Benzinga
News headline image
Gilead Sciences Stock Crashes 9% After Cancer Drug Fails A Key Test ↗
The company had hoped Trodelvy would extend overall survival for patients with a form of lung cancer. 
Via Investor's Business Daily
News headline image
EXCLUSIVE: The 'Buy Everything' Market Is Over: Synopsys-Ansys Merger Provides Fertile Ground For This Stock Picker ↗
The "buy everything" sentiment that powered equity indices higher last quarter is over. It's a stock picker's market, Marc Chaikin says. 
Via Benzinga
News headline image
AbbVie, Arch Capital, Gilead Sciences And A Telecom Giant On CNBC's 'Final Trades' ↗
On CNBC’s "Halftime Report Final Trades," Rob Sechan of NewEdge Wealth said Gilead Sciences, Inc. 
Via Benzinga
News headline image
AbbVie's Strategic Move: ImmunoGen Acquisition Triggers Golden Cross, Yet Valuation Caution Remains ↗
AbbVie Inc (ABBV) stock is up 15% since acquiring ImmunoGen, but past Golden Cross rallies haven't sustained. With high valuation and competition, investors may want to wait for a pullback. 
Via Benzinga
News headline image
Gilead’s Quiet Revolution: Is GILD the Next Big Stock to Soar? ↗
While Wall Street obsesses over weight-loss drugs, Gilead Sciences is working on life-saving treatments and GILD stock looks ready to rally. 
Via InvestorPlace
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Nasdaq 100 Snaps Longest Negative Streak In 14 Months As Tech Stocks Find Relief On Mixed Data ↗
The Nasdaq 100 ended the first week of 2024 on a positive note, ending a five-session losing streak, despite volatile trading and conflicting economic data. 
Via Benzinga
News headline image
This Analyst Downgrades Bristol-Myers Squibb, Cautions Amid Product Launch And Revenue Concerns ↗
BofA Securities downgraded Bristol-Myers Squibb & Co (NYSE: BMY), noting that initially, the analyst believed that Bristol's loss of exclusivity (LOEs) for drugs like Eliquis and Opdivo was widely... 
Via Benzinga
< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
51 52 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.